NVO Jan 2025 65.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:59AM EDT. Market open.
| Previous close | 62.69 |
| Open | 62.69 |
| Bid | 70.35 |
| Ask | 74.65 |
| Strike | 65.00 |
| Expiry date | 2025-01-17 |
| Day's range | 62.69 - 62.69 |
| Contract range | N/A |
| Volume | |
| Open interest | 106 |
The TelegraphNestle to sell supplements that tackle ‘Ozempic face’
Nestlé is to target “Ozempic face” by selling dietary supplements to counteract the effects of weight-loss drugs.
GlobeNewswireNovo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8 Bagsværd, Denmark, 23 June 2024 – Novo Nordisk announced results from the phase 3 FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment (regular treatment to prevent prolonged and spontaneous bleeding) w
ZacksNovo Nordisk (NVO) Gains As Market Dips: What You Should Know
In the most recent trading session, Novo Nordisk (NVO) closed at $140.99, indicating a +0.13% shift from the previous trading day.
© 2024 Yahoo. All rights reserved.